Carlsmed, Inc. Common Stock (CARL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Carlsmed, Inc. Common Stock stock (CARL) is currently trading at $10.19. Carlsmed, Inc. Common Stock PS ratio (Price-to-Sales) is 5.29. Analyst consensus price target for CARL is $19.60. WallStSmart rates CARL as Sell.
- CARL PE ratio analysis and historical PE chart
- CARL PS ratio (Price-to-Sales) history and trend
- CARL intrinsic value — DCF, Graham Number, EPV models
- CARL stock price prediction 2025 2026 2027 2028 2029 2030
- CARL fair value vs current price
- CARL insider transactions and insider buying
- Is CARL undervalued or overvalued?
- Carlsmed, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- CARL Piotroski F-Score and Altman Z-Score
- CARL analyst price target and Smart Rating
Carlsmed, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Carlsmed, Inc. Common Stock (CARL) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around operating margin and profit margin. Significant fundamental concerns warrant caution or avoidance.
Carlsmed, Inc. Common Stock (CARL) Key Strengths (1)
Revenue surging 98.40% year-over-year
Supporting Valuation Data
Carlsmed, Inc. Common Stock (CARL) Areas to Watch (6)
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 7.26%
Premium valuation at 5.3x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Carlsmed, Inc. Common Stock (CARL) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 98.40%.
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Institutional Own.. Some valuation metrics including Price/Sales (5.29), Price/Book (2.70) suggest expensive pricing. Profitability pressure is visible in Operating Margin at -69.10%, Profit Margin at -57.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -69.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 98.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CARL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CARL's Price-to-Sales ratio of 5.29x trades 42% below its historical average of 9.17x (0th percentile). The current valuation is 67% below its historical high of 15.93x set in Nov 2025, and 0% above its historical low of 5.29x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~13.0x as trailing revenue scaled faster than the stock price.
Compare CARL with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Carlsmed, Inc. Common Stock (CARL) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Carlsmed, Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 45M with 98% growth year-over-year. The company is currently unprofitable, posting a -57.5% profit margin.
Key Findings
Revenue growing at 98% YoY, reaching 45M. This pace significantly outperforms most HEALTH INFORMATION SERVICES peers.
The company is unprofitable with a -57.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Carlsmed, Inc. Common Stock maintain 98%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Carlsmed, Inc. Common Stock.
Bottom Line
Carlsmed, Inc. Common Stock is a high-conviction growth story with revenue accelerating at 98% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -57.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Carlsmed, Inc. Common Stock(CARL)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.